Download PDF
CC BY 4.0 · Glob Med Genet 2020; 07(03): 092-094
DOI: 10.1055/s-0040-1721080
Rapid Communication

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Codon Usage and Replicative Fitness

Darja Kanduc 
1   Department of Biosciences, Biotechnologies, and Biopharmaceutics, University of Bari, Bari, Italy
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) codon usage, as shown by the polyprotein coding sequence, shows better translation potential in the human host when compared with human coronavirus OC43 (HCoV-OC43) codon usage. Such translational advantage might facilitate SARS-CoV-2 replication, immunogenicity, and pathogenicity, thus also accounting for the less harmful character of HCoV-OC43 infection.

Keywords

codon usage - HCoV-OC43 - SARS-CoV-2 - viral replication fitness

Supplementary Material



Publication History

Article published online:
02 December 2020

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis 2020; 71 (15) 769-777
    CrossrefPubMedGoogle Scholar
  • 2 Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res 2008; 133 (01) 13-19
    CrossrefPubMedGoogle Scholar
  • 3 Kanduc D. From anti-SARS-CoV-2 immune responses to COVID-19 via molecular mimicry. Antibodies (Basel) 2020; 9 (03) E33
    CrossrefPubMedGoogle Scholar
  • 4 Lin YS, Lin CF, Fang YT. et al. Antibody to severe acute respiratory syndrome (SARS)-associated coronavirus spike protein domain 2 cross-reacts with lung epithelial cells and causes cytotoxicity. Clin Exp Immunol 2005; 141 (03) 500-508
    CrossrefPubMedGoogle Scholar
  • 5 Kanduc D, Shoenfeld Y. On the molecular determinants of the SARS-CoV-2 attack. Clin Immunol 2020; 215: 108426
    CrossrefPubMedGoogle Scholar
  • 6 Zhao J, Yuan Q, Wang H. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020; (e-pub ahead of print). DOI: 10.1093/cid/ciaa344.
    CrossrefPubMedGoogle Scholar
  • 7 Lim YX, Ng YL, Tam JP, Liu DX. Human coronaviruses: a review of virus–host interactions. Diseases 2016; 4 (03) 26
    CrossrefPubMedGoogle Scholar
  • 8 Kanduc D. Role of codon usage and tRNA changes in rat cytomegalovirus latency and (re)activation. J Basic Microbiol 2016; 56 (06) 617-626
    CrossrefPubMedGoogle Scholar
  • 9 Kanduc D. Rare human codons and HCMV translational regulation. J Mol Microbiol Biotechnol 2017; 27 (04) 213-216
    CrossrefPubMedGoogle Scholar
  • 10 Nakamura Y, Gojobori T, Ikemura T. Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res 2000; 28 (01) 292
    CrossrefPubMedGoogle Scholar
  • 11 Quax TE, Claassens NJ, Söll D, van der Oost J. Codon bias as a means to fine-tune gene expression. Mol Cell 2015; 59 (02) 149-161
    CrossrefPubMedGoogle Scholar
  • 12 Supek F. The code of silence: widespread associations between synonymous codon biases and gene function. J Mol Evol 2016; 82 (01) 65-73
    CrossrefPubMedGoogle Scholar
  • 13 Tijms MA, Nedialkova DD, Zevenhoven-Dobbe JC, Gorbalenya AE, Snijder EJ. Arterivirus subgenomic mRNA synthesis and virion biogenesis depend on the multifunctional nsp1 autoprotease. J Virol 2007; 81 (19) 10496-10505
    CrossrefPubMedGoogle Scholar
  • 14 Krichel B, Falke S, Hilgenfeld R, Redecke L, Uetrecht C. Processing of the SARS-CoV pp1a/ab nsp7-10 region. Biochem J 2020; 477 (05) 1009-1019
    CrossrefPubMedGoogle Scholar
  • 15 Agrawal AS, Tao X, Algaissi A. et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother 2016; 12 (09) 2351-2356
    CrossrefPubMedGoogle Scholar
  • 16 Cameron MJ, Kelvin AA, Leon AJ. et al. Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model. PLoS One 2012; 7 (09) e45842
    CrossrefPubMedGoogle Scholar
  • 17 Tseng CT, Sbrana E, Iwata-Yoshikawa N. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 2012; 7 (04) e35421
    CrossrefPubMedGoogle Scholar
  • 18 Yasui F, Kai C, Kitabatake M. et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol 2008; 181 (09) 6337-6348
    CrossrefPubMedGoogle Scholar
  • 19 Kanduc D, Shoenfeld Y. Inter-pathogen peptide sharing and the original antigenic sin: solving a paradox. Open Immunol J 2018; 8: 16-27
    CrossrefGoogle Scholar
  • 20 Kanduc D. Immunogenicity, Immunopathogenicity, and Immunotolerance in One Graph. Anticancer Agents Med Chem 2015; 15: 1264-1268 . Doi: 10.2174/1871520615666150716105543
    CrossrefPubMedGoogle Scholar
  • 21 Kanduc D. Hydrophobicity and the Physico-Chemical Basis of Immunotolerance. Pathobiology 2020; 87: 268-276
    CrossrefPubMedGoogle Scholar